Michiel van Den Brand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michiel van Den Brand has a total of 218 co-authors. Here are the top co-authors by number of shared publications:
- Johan Hjm van Krieken
Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
12 shared publications - Blanca Scheijen
Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
8 shared publications - Patricia J. T. A. Groenen
Department of Pathology Radboud university medical center Nijmegen The Netherlands
8 shared publications - Leticia Quintanilla-Martinez
Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany
7 shared publications - Camille Laurent
Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1037, Centre de Recherche en Cancérologie de Toulouse (CRCT), Toulouse, France. Centre National de la Recherche Scientifique (CNRS) UMR5071, Toulouse, France Université de Toulouse III-Paul Sabatier, 31037 Toulouse, France
6 shared publications - Ioannis Anagnostopoulos
Institute of Pathology University of Würzburg Würzburg Germany
6 shared publications
Latest Publications
- Open Access
- 15 December 2025
- Published by Wiley in Histopathology
- Vol. 88 (5) , 1059-1074
Next‐generation sequencing‐based IG clonality analysis to discriminate reactive infiltrates from minimal lymphoma involvement in paired lymphoma and bone marrow biopsies; a EuroClonality ‐ NGS Working Group study
Aims: Bone marrow (BM) biopsy is an important procedure in B‐cell lymphoma staging. In most biopsies, the presence or absence of a lymphoma infiltrate can reliably be determined by standard histology. However, in a subset of cases with limited infiltration, this assessment remains inconclusive, requiring an alternative approach. Next‐generation sequencing (NGS)‐based detection of immunoglobulin (IG) gene rearrangements has the potential for resolving these difficult cases because of its high sensitivity. In this study, we tested the NGS‐based IG clonality protocol developed by the EuroClonality‐NGS Working Group on BM staging biopsies. Methods and results: Forty‐nine BM biopsies ranging from morphologically and immunohistochemically evidently involved to negative were analysed and compared to the original lymphoma. A clear distinction in the abundance of overlapping clonal IG rearrangements was observed between BM biopsies that were positive versus negative for lymphoma based on morphology and immunohistochemistry. In the 12 BM biopsies in which morphology and immunohistochemistry were insufficient to differentiate between the presence or absence of lymphoma, the estimated B‐cell infiltration ranged from 1% to 5%. In these cases, NGS‐based IG clonality analysis of paired primary lymphoma/BM biopsies provided a binary outcome; a subset of cases with hardly or no primary lymphoma‐derived IG gene rearrangements in the BM biopsy could be distinguished from cases with clear presence of primary lymphoma‐derived IG gene rearrangements. Conclusions: Our data demonstrated that paired NGS‐based IG clonality analysis of lymphoma and BM samples can be a valuable additional tool for difficult BM staging biopsies in patients with B‐cell lymphoma.
- 15 December 2025
- Published by Wiley in Histopathology
- Vol. 88 (5) , 1059-1074
Open AccessNext‐generation sequencing‐based IG clonality analysis to discriminate reactive infiltrates from minimal lymphoma involvement in paired lymphoma and bone marrow biopsies; a EuroClonality ‐ NGS Working Group study
Aims: Bone marrow (BM) biopsy is an important procedure in B‐cell lymphoma staging. In most biopsies, the presence or absence of a lymphoma infiltrate can reliably be determined by standard histology. However, in a subset of cases with limited infiltration, this assessment remains inconclusive, requiring an alternative approach. Next‐generation sequencing (NGS)‐based detection of immunoglobulin (IG) gene rearrangements has the potential for resolving these difficult cases because of its high sensitivity. In this study, we tested the NGS‐based IG clonality protocol developed by the EuroClonality‐NGS Working Group on BM staging biopsies. Methods and results: Forty‐nine BM biopsies ranging from morphologically and immunohistochemically evidently involved to negative were analysed and compared to the original lymphoma. A clear distinction in the abundance of overlapping clonal IG rearrangements was observed between BM biopsies that were positive versus negative for lymphoma based on morphology and immunohistochemistry. In the 12 BM biopsies in which morphology and immunohistochemistry were insufficient to differentiate between the presence or absence of lymphoma, the estimated B‐cell infiltration ranged from 1% to 5%. In these cases, NGS‐based IG clonality analysis of paired primary lymphoma/BM biopsies provided a binary outcome; a subset of cases with hardly or no primary lymphoma‐derived IG gene rearrangements in the BM biopsy could be distinguished from cases with clear presence of primary lymphoma‐derived IG gene rearrangements. Conclusions: Our data demonstrated that paired NGS‐based IG clonality analysis of lymphoma and BM samples can be a valuable additional tool for difficult BM staging biopsies in patients with B‐cell lymphoma.
- Open Access
- 13 October 2025
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 66 (13) , 2504-2517
Challenges in predicting outcomes for watch and wait follicular lymphoma patients: insights into clinical, pathological, and molecular factors
Follicular lymphoma (FL) exhibits considerable heterogeneity in clinical trajectories and molecular characteristics. This study assessed the association between clinical presentation, histopathological findings, and mutational profiles with the duration of a Watch-and-Wait (WW) strategy in a cohort of 124 FL patients managed with a WW approach at diagnosis. Median event-free survival (EFS) (time to treatment or death) was 29 months. Hemoglobin below B2M mutations and high m7-FLIPI score correlated with inferior EFS, though present in only 4% and 15% of cases, respectively. WW patients were compared to 91 patients receiving upfront immunochemotherapy to evaluate the differences in prognostic factors and mutational profiles. Despite distinct clinical prognostic factors, mutational profiles were comparable between the two groups, even at clinical extremes. These findings underscore the challenges in predicting the duration of a WW approach.
- 13 October 2025
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 66 (13) , 2504-2517
Open AccessChallenges in predicting outcomes for watch and wait follicular lymphoma patients: insights into clinical, pathological, and molecular factors
Follicular lymphoma (FL) exhibits considerable heterogeneity in clinical trajectories and molecular characteristics. This study assessed the association between clinical presentation, histopathological findings, and mutational profiles with the duration of a Watch-and-Wait (WW) strategy in a cohort of 124 FL patients managed with a WW approach at diagnosis. Median event-free survival (EFS) (time to treatment or death) was 29 months. Hemoglobin below B2M mutations and high m7-FLIPI score correlated with inferior EFS, though present in only 4% and 15% of cases, respectively. WW patients were compared to 91 patients receiving upfront immunochemotherapy to evaluate the differences in prognostic factors and mutational profiles. Despite distinct clinical prognostic factors, mutational profiles were comparable between the two groups, even at clinical extremes. These findings underscore the challenges in predicting the duration of a WW approach.
- Open Access
- 13 August 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 287-307
Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop
The challenging boundaries between neoplastic and reactive lymphoproliferations were discussed during the 2024 European Association for Haematopathology/Society for Hematopathology workshop in Dubrovnik, Croatia. Session 3 focussed on the atypical lymphoid proliferations associated with therapeutic interventions. Forty-four cases were submitted representing a broad spectrum of lymphoproliferative disorders (LPDs) encountered in the settings of immunosuppressive and immunomodulatory therapies, various interventions for solid tumor treatment, drug reaction with eosinophilia and systemic symptoms (DRESS), CAR T-cell therapy for B-cell lymphomas, Bruton tyrosine kinase inhibitors (BTKI) for SLL/CLL treatment, ABL-kinase inhibitor dasatinib, and COVID-19 vaccination. The cases of this session highlighted the importance of having sufficient clinical information including drug history and distribution of disease in order to achieve reliable diagnosis. Among LPDs associated with immunosuppressive and immunomodulatory therapies, the most challenging were T- and NK-derived infiltrates as they ranged from non-clonal to clonal. DRESS-associated lymphadenopathy exhibited variable histologic patterns with the most difficult differential diagnosis being with a T-cell lymphoma. LPDs observed after CAR T-cell therapy for B-cell neoplasms exhibited unexpected phenotypes resulting either from lineage switching/transdifferentiation, or from harvested T-cells already harbouring cancer-associated variants. Temporary interruption of BTKI treatment for CLL/SLL due to surgical procedures led to a “Pseudo-Richter transformation” that disappeared after reintroduction of therapy. Dasatinib led to a lymphadenopathy with a peculiar florid follicular hyperplasia that regressed after discontinuation of therapy. The findings of the few thoroughly studied COVID-19 vaccination associated lymphadenopathy cases reflected a disordered immune response. This report describes the most important features for diagnosis of these challenging cases.
- 13 August 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 287-307
Open AccessAtypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop
The challenging boundaries between neoplastic and reactive lymphoproliferations were discussed during the 2024 European Association for Haematopathology/Society for Hematopathology workshop in Dubrovnik, Croatia. Session 3 focussed on the atypical lymphoid proliferations associated with therapeutic interventions. Forty-four cases were submitted representing a broad spectrum of lymphoproliferative disorders (LPDs) encountered in the settings of immunosuppressive and immunomodulatory therapies, various interventions for solid tumor treatment, drug reaction with eosinophilia and systemic symptoms (DRESS), CAR T-cell therapy for B-cell lymphomas, Bruton tyrosine kinase inhibitors (BTKI) for SLL/CLL treatment, ABL-kinase inhibitor dasatinib, and COVID-19 vaccination. The cases of this session highlighted the importance of having sufficient clinical information including drug history and distribution of disease in order to achieve reliable diagnosis. Among LPDs associated with immunosuppressive and immunomodulatory therapies, the most challenging were T- and NK-derived infiltrates as they ranged from non-clonal to clonal. DRESS-associated lymphadenopathy exhibited variable histologic patterns with the most difficult differential diagnosis being with a T-cell lymphoma. LPDs observed after CAR T-cell therapy for B-cell neoplasms exhibited unexpected phenotypes resulting either from lineage switching/transdifferentiation, or from harvested T-cells already harbouring cancer-associated variants. Temporary interruption of BTKI treatment for CLL/SLL due to surgical procedures led to a “Pseudo-Richter transformation” that disappeared after reintroduction of therapy. Dasatinib led to a lymphadenopathy with a peculiar florid follicular hyperplasia that regressed after discontinuation of therapy. The findings of the few thoroughly studied COVID-19 vaccination associated lymphadenopathy cases reflected a disordered immune response. This report describes the most important features for diagnosis of these challenging cases.
- Open Access
- 1 August 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 275-286
Atypical lymphoproliferations associated with germline genetic variants: a report of the 2024 EA4HP/SH lymphoma workshop
Session 2 of the 2024 European Association for Haematopathology/Society for Hematopathology lymphoma workshop was dedicated to atypical lymphoproliferations in association with germline genetic variants. The first group of cases were lymphoproliferations occurring in the context of primary immunodeficiencies (PID), a heterogeneous group of diseases with increasing incidence and number of different diseases due to better recognition. The workshop contained a spectrum of different PIDs and associated lymphoproliferations with autoimmune lymphoproliferative syndrome, activated phosphoinositide 3-kinase delta syndrome, ataxia-telangiectasia and common variable immune deficiency being the most common. Both children and adults were affected, and the diagnosis of an underlying PID often required a high index of suspicion and correlation with clinical presentation and immunological/ infectious workup. Recognition of a PID allows specific treatment and can influence the interpretation of lymphoproliferations occurring in this context. The spectrum of lymphoproliferations ranged from reactive to overt lymphoma, both EBV-positive and -negative. In a subset of cases, it was very difficult or impossible to establish the boundary between reactive and neoplastic in the context of a PID. The second group represented a heterogeneous group of lymphoproliferations in the context of mutations in germline haematopoietic malignancy risk genes, without associated immunodeficiency. It was often difficult to determine if the genetic defect and the lymphoproliferation were causally related or coincidental, especially if the patient was also treated for non-lymphoid conditions. This is a rapidly evolving field in which future studies are expected to shed more light on the relationship between germline mutations and lymphoid malignancy.
- 1 August 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 275-286
Open AccessAtypical lymphoproliferations associated with germline genetic variants: a report of the 2024 EA4HP/SH lymphoma workshop
Session 2 of the 2024 European Association for Haematopathology/Society for Hematopathology lymphoma workshop was dedicated to atypical lymphoproliferations in association with germline genetic variants. The first group of cases were lymphoproliferations occurring in the context of primary immunodeficiencies (PID), a heterogeneous group of diseases with increasing incidence and number of different diseases due to better recognition. The workshop contained a spectrum of different PIDs and associated lymphoproliferations with autoimmune lymphoproliferative syndrome, activated phosphoinositide 3-kinase delta syndrome, ataxia-telangiectasia and common variable immune deficiency being the most common. Both children and adults were affected, and the diagnosis of an underlying PID often required a high index of suspicion and correlation with clinical presentation and immunological/ infectious workup. Recognition of a PID allows specific treatment and can influence the interpretation of lymphoproliferations occurring in this context. The spectrum of lymphoproliferations ranged from reactive to overt lymphoma, both EBV-positive and -negative. In a subset of cases, it was very difficult or impossible to establish the boundary between reactive and neoplastic in the context of a PID. The second group represented a heterogeneous group of lymphoproliferations in the context of mutations in germline haematopoietic malignancy risk genes, without associated immunodeficiency. It was often difficult to determine if the genetic defect and the lymphoproliferation were causally related or coincidental, especially if the patient was also treated for non-lymphoid conditions. This is a rapidly evolving field in which future studies are expected to shed more light on the relationship between germline mutations and lymphoid malignancy.
- 23 July 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 309-325
Indolent pediatric lymphomas/lymphoproliferative disorders: a report of the 2024 EA4HP/SH lymphoma workshop
The boundaries between indolent neoplastic and reactive lymphoproliferations were discussed during the 2024 European Association for Haematopathology/Society for Hematopathology workshop in Dubrovnik, Croatia. Session 4 focused on the revision of indolent pediatric lymphoid neoplasms/lymphoproliferations. Forty-one cases were submitted, representing good examples of indolent pediatric lymphomas/lymphoproliferations and their diagnostic challenges. The morphologic spectrum of pediatric-type follicular lymphoma (PTFL) was discussed, especially exploring unifying features of cases with and without marginal zone differentiation (MZD) (the first also referred to as pediatric nodal marginal zone lymphoma). Unusual features like relapses/recurrences; extranodal involvement and high proliferation rate in the marginal zone differentiated component were observed in PTFL with or without MZD. Rare follicle center-derived neoplasms occurring in children other than PTFL where discussed, such as primary testicular follicular lymphoma and follicle center lymphoma of the lower female genital tract. Testicular follicular lymphomas were compared to cases known from literature, defining a better picture of their clinicopathological features. The criteria for the diagnosis of atypical lymphoid hyperplasia were reviewed and nodal and extranodal cases are discussed. Plasmacytic proliferations in the pediatric population are exceedingly rare, but do exist in clonal and non-clonal forms. A heterogeneous group of extranodal lymphomas is included, among them extranodal marginal zone lymphomas (MZL) of the stomach with a large cell transformation and an intramuscular MZL with comparable features of a cutaneous MZL/lymphoproliferation with IgG4 expression. In this report, the different spectrum of indolent pediatric lymphomas compared to the adult counterpart will be highlighted, to avoid misdiagnosis and overtreatment.
- 23 July 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 309-325
Indolent pediatric lymphomas/lymphoproliferative disorders: a report of the 2024 EA4HP/SH lymphoma workshop
The boundaries between indolent neoplastic and reactive lymphoproliferations were discussed during the 2024 European Association for Haematopathology/Society for Hematopathology workshop in Dubrovnik, Croatia. Session 4 focused on the revision of indolent pediatric lymphoid neoplasms/lymphoproliferations. Forty-one cases were submitted, representing good examples of indolent pediatric lymphomas/lymphoproliferations and their diagnostic challenges. The morphologic spectrum of pediatric-type follicular lymphoma (PTFL) was discussed, especially exploring unifying features of cases with and without marginal zone differentiation (MZD) (the first also referred to as pediatric nodal marginal zone lymphoma). Unusual features like relapses/recurrences; extranodal involvement and high proliferation rate in the marginal zone differentiated component were observed in PTFL with or without MZD. Rare follicle center-derived neoplasms occurring in children other than PTFL where discussed, such as primary testicular follicular lymphoma and follicle center lymphoma of the lower female genital tract. Testicular follicular lymphomas were compared to cases known from literature, defining a better picture of their clinicopathological features. The criteria for the diagnosis of atypical lymphoid hyperplasia were reviewed and nodal and extranodal cases are discussed. Plasmacytic proliferations in the pediatric population are exceedingly rare, but do exist in clonal and non-clonal forms. A heterogeneous group of extranodal lymphomas is included, among them extranodal marginal zone lymphomas (MZL) of the stomach with a large cell transformation and an intramuscular MZL with comparable features of a cutaneous MZL/lymphoproliferation with IgG4 expression. In this report, the different spectrum of indolent pediatric lymphomas compared to the adult counterpart will be highlighted, to avoid misdiagnosis and overtreatment.
- Open Access
- 12 July 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 253-273
The morphological spectrum of Castleman disease and related disorders: a report from the Lymphoma Workshop of the 22nd Meeting of the European Association of Hematopathology
Castleman disease (CD) is an intriguing and complicated group of local and systemic disorders mainly affecting lymph nodes with heterogeneous presentation and therapeutic needs. These disorders were the topic of Session 1 of the Lymphoma Workshop at the 2024 EA4HP in Dubrovnik, Croatia. In this report, we summarize the features of the 85 submitted cases and review the differential diagnosis, pitfalls, and advances for all CD subtypes. Specifically, the molecular landscape of unicentric CD and its relationship with follicular dendritic cell proliferations and indolent T-lymphoblastic proliferation will be discussed. The spectrum of idiopathic multicentric CD (MCD), TAFRO syndrome, as well as the clinical and histopathological peculiarities of POEMS-CD, is reviewed. Cases of Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV8) + MCD were the most complicated and well demonstrated the difficulties and overlaps in the differential diagnosis of KSHV/HHV8 + lymphoproliferative disorders. Finally, the important topic of CD mimickers will be addressed, demonstrating how the integration of clinical, laboratory, histopathological, and molecular data is mandatory to confirm a diagnosis of CD and how to distinguish it from the many neoplastic, autoimmune, and infective mimickers.
- 12 July 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 253-273
Open AccessThe morphological spectrum of Castleman disease and related disorders: a report from the Lymphoma Workshop of the 22nd Meeting of the European Association of Hematopathology
Castleman disease (CD) is an intriguing and complicated group of local and systemic disorders mainly affecting lymph nodes with heterogeneous presentation and therapeutic needs. These disorders were the topic of Session 1 of the Lymphoma Workshop at the 2024 EA4HP in Dubrovnik, Croatia. In this report, we summarize the features of the 85 submitted cases and review the differential diagnosis, pitfalls, and advances for all CD subtypes. Specifically, the molecular landscape of unicentric CD and its relationship with follicular dendritic cell proliferations and indolent T-lymphoblastic proliferation will be discussed. The spectrum of idiopathic multicentric CD (MCD), TAFRO syndrome, as well as the clinical and histopathological peculiarities of POEMS-CD, is reviewed. Cases of Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV8) + MCD were the most complicated and well demonstrated the difficulties and overlaps in the differential diagnosis of KSHV/HHV8 + lymphoproliferative disorders. Finally, the important topic of CD mimickers will be addressed, demonstrating how the integration of clinical, laboratory, histopathological, and molecular data is mandatory to confirm a diagnosis of CD and how to distinguish it from the many neoplastic, autoimmune, and infective mimickers.
- Open Access
- 5 July 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 327-347
Exploring the boundaries between neoplastic and reactive lymphoproliferations: lymphoid neoplasms with indolent behavior and clonal lymphoproliferations—a report of the 2024 EA4HP/SH lymphoma workshop
The boundaries between neoplastic and reactive lymphoproliferations were discussed during the 2024 European Association for Haematopathology/Society for Hematopathology workshop in Dubrovnik, Croatia. Session 5 focused on indolent lymphoid neoplasms and clonal lymphoproliferations. Seventy-two cases were submitted, representing good examples of indolent lymphomas and lymphoproliferative disorders (LPD) and their diagnostic challenges. The morphologic spectrum of primary cutaneous marginal zone lymphoma/lymphoproliferation (PC-MZL/PC-MZLPD) was discussed. PC-MZL/PC-MZLPD is divided in the immunoglobulin heavy chain switched-type and non-switched-type with some clinicopathological differences. The overlapping features between PC-MZL/PC-MZLPD and PC-CD4 + T-cell LPD were highlighted. The criteria for the diagnosis of indolent T-lymphoblastic proliferation (iT-LBP) were reviewed. Indolent T-cell lymphoproliferation of the gastrointestinal tract (iT-LPD-GI) is a rare clonal, non-destructive, and non-epitheliotropic T-cell LPD occurring in adults with a male predominance. The cases submitted to the workshop revealed clinicopathological heterogeneity. Unusual features like infiltration of the complete intestinal wall, mesenteric lymph node involvement, and splenomegaly were observed. A novel group of PD1 + /CD4 + indolent cases with intestinal tropism and dissemination to blood, bone marrow, lymph node, and skin was identified. Other indolent clonal B- and T-cell LPDs were discussed including transient, clonal CD8 + T-cell proliferations, usually the result of immune-mediated cytotoxic T-cell response to virus or neoantigens, and the recently described follicle center lymphoma (FLC) of the lower female genital tract. The increasing awareness of the existence of indolent LPDs should avoid unnecessary treatments. In this report, novel findings, recommendations for diagnosis, open questions, and diagnostic challenges raised by the cases submitted to the workshop will be discussed.
- 5 July 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 327-347
Open AccessExploring the boundaries between neoplastic and reactive lymphoproliferations: lymphoid neoplasms with indolent behavior and clonal lymphoproliferations—a report of the 2024 EA4HP/SH lymphoma workshop
The boundaries between neoplastic and reactive lymphoproliferations were discussed during the 2024 European Association for Haematopathology/Society for Hematopathology workshop in Dubrovnik, Croatia. Session 5 focused on indolent lymphoid neoplasms and clonal lymphoproliferations. Seventy-two cases were submitted, representing good examples of indolent lymphomas and lymphoproliferative disorders (LPD) and their diagnostic challenges. The morphologic spectrum of primary cutaneous marginal zone lymphoma/lymphoproliferation (PC-MZL/PC-MZLPD) was discussed. PC-MZL/PC-MZLPD is divided in the immunoglobulin heavy chain switched-type and non-switched-type with some clinicopathological differences. The overlapping features between PC-MZL/PC-MZLPD and PC-CD4 + T-cell LPD were highlighted. The criteria for the diagnosis of indolent T-lymphoblastic proliferation (iT-LBP) were reviewed. Indolent T-cell lymphoproliferation of the gastrointestinal tract (iT-LPD-GI) is a rare clonal, non-destructive, and non-epitheliotropic T-cell LPD occurring in adults with a male predominance. The cases submitted to the workshop revealed clinicopathological heterogeneity. Unusual features like infiltration of the complete intestinal wall, mesenteric lymph node involvement, and splenomegaly were observed. A novel group of PD1 + /CD4 + indolent cases with intestinal tropism and dissemination to blood, bone marrow, lymph node, and skin was identified. Other indolent clonal B- and T-cell LPDs were discussed including transient, clonal CD8 + T-cell proliferations, usually the result of immune-mediated cytotoxic T-cell response to virus or neoantigens, and the recently described follicle center lymphoma (FLC) of the lower female genital tract. The increasing awareness of the existence of indolent LPDs should avoid unnecessary treatments. In this report, novel findings, recommendations for diagnosis, open questions, and diagnostic challenges raised by the cases submitted to the workshop will be discussed.
- Open Access
- 4 June 2025
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 82 (1) , 1-14
CD151 interacts with integrin beta 2 in B cell lymphomas
CD151 is a broadly expressed four-transmembrane protein (tetraspanin) that interacts with laminin‐binding integrins like integrin alpha 3 (ITGA3). CD151 drives tumor development and expression correlates with poor prognosis in solid cancers, but CD151 has not been studied in B cell malignancies. We investigated CD151 expression on normal human B cells and B cell lymphomas using highly sensitive flow cytometry and immunohistochemistry. Expression of CD151 increased during B cell differentiation from naïve to memory B cells to plasma cells. B lymphoma cell lines and human lymphoma biopsy samples expressed higher levels of CD151 compared to normal B cells, but CD151‐deficient lymphomas were identified as well. To investigate the function of CD151 in B cells, CD151‐deficient and stably transduced CD151 expressing B lymphoma cell lines were generated. Immunoprecipitation-mass spectrometry analysis of CD151 protein complexes identified integrin beta 2 (ITGB2) as new interaction partner in lymphoma cells. Deficiency of CD151 decreased cell surface expression of alpha integrin subunits L (ITGAL) and M (ITGAM), and impaired ICAM-1-mediated cell spreading. Interestingly, B cells and lymphomas did not express ITGA3‐bound CD151 compared to T cells that expressed two different populations of integrin‐bound and integrin‐free CD151. Despite CD151 expression not being related to clinical outcome of patients with diffuse large B cell lymphoma (DLBCL), CD151 expression was predominantly detected in the activated (ABC) subset of DLBCL. Taken together, we identified a new molecular association of CD151 with ITGB2, and targeting integrin-free CD151 in DLBCL may represent a new target for immunotherapy.
- 4 June 2025
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 82 (1) , 1-14
Open AccessCD151 interacts with integrin beta 2 in B cell lymphomas
CD151 is a broadly expressed four-transmembrane protein (tetraspanin) that interacts with laminin‐binding integrins like integrin alpha 3 (ITGA3). CD151 drives tumor development and expression correlates with poor prognosis in solid cancers, but CD151 has not been studied in B cell malignancies. We investigated CD151 expression on normal human B cells and B cell lymphomas using highly sensitive flow cytometry and immunohistochemistry. Expression of CD151 increased during B cell differentiation from naïve to memory B cells to plasma cells. B lymphoma cell lines and human lymphoma biopsy samples expressed higher levels of CD151 compared to normal B cells, but CD151‐deficient lymphomas were identified as well. To investigate the function of CD151 in B cells, CD151‐deficient and stably transduced CD151 expressing B lymphoma cell lines were generated. Immunoprecipitation-mass spectrometry analysis of CD151 protein complexes identified integrin beta 2 (ITGB2) as new interaction partner in lymphoma cells. Deficiency of CD151 decreased cell surface expression of alpha integrin subunits L (ITGAL) and M (ITGAM), and impaired ICAM-1-mediated cell spreading. Interestingly, B cells and lymphomas did not express ITGA3‐bound CD151 compared to T cells that expressed two different populations of integrin‐bound and integrin‐free CD151. Despite CD151 expression not being related to clinical outcome of patients with diffuse large B cell lymphoma (DLBCL), CD151 expression was predominantly detected in the activated (ABC) subset of DLBCL. Taken together, we identified a new molecular association of CD151 with ITGB2, and targeting integrin-free CD151 in DLBCL may represent a new target for immunotherapy.
- Open Access
- 22 October 2024
- Published by Wiley in Histopathology
- Vol. 86 (1) , 58-68
Role of artificial intelligence in haematolymphoid diagnostics
The advent of digital pathology and the deployment of high‐throughput molecular techniques are generating an unprecedented mass of data. Thanks to advances in computational sciences, artificial intelligence (AI) approaches represent a promising avenue for extracting relevant information from complex data structures. From diagnostic assistance to powerful research tools, the potential fields of application of machine learning techniques in pathology are vast and constitute the subject of considerable research work. The aim of this article is to provide an overview of the potential applications of AI in the field of haematopathology and to define the role that these emerging technologies could play in our laboratories in the short to medium term.
- 22 October 2024
- Published by Wiley in Histopathology
- Vol. 86 (1) , 58-68
Open AccessRole of artificial intelligence in haematolymphoid diagnostics
The advent of digital pathology and the deployment of high‐throughput molecular techniques are generating an unprecedented mass of data. Thanks to advances in computational sciences, artificial intelligence (AI) approaches represent a promising avenue for extracting relevant information from complex data structures. From diagnostic assistance to powerful research tools, the potential fields of application of machine learning techniques in pathology are vast and constitute the subject of considerable research work. The aim of this article is to provide an overview of the potential applications of AI in the field of haematopathology and to define the role that these emerging technologies could play in our laboratories in the short to medium term.
- Open Access
- 11 September 2023
- Published by Springer Nature in Virchows Archiv
- Vol. 483 (3) , 437
Correction to: The many faces of nodal and splenic marginal zone lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop
- 11 September 2023
- Published by Springer Nature in Virchows Archiv
- Vol. 483 (3) , 437
Open AccessCorrection to: The many faces of nodal and splenic marginal zone lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop